356092-74-5

Basic information

• Product Name: CYCLOPENTYL-(2,4-DIMETHOXY-BENZYL)-AMINE
• Synonyms: CYCLOPENTYL-(2,4-DIMETHOXY-BENZYL)-AMINE;CHEMBRDG-BB 5562574;AKOS JY2024799;N-(2,4-DIMETHOXYBENZYL)CYCLOPENTANAMINE;UKRORGSYN-BB BBV-119967;N-(2,4-dimethoxybenzyl)cyclopentanamine(SALTDATA: HBr)
• CAS NO: 356092-74-5
• Molecular Formula: C₁₄H₂₁NO₂
• Molecular Weight: 235.32
• Mol File: 356092-74-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 348.2°C at 760 mmHg
• Flash Point: 145.2°C
• Appearance: /
• Density: 1.05g/cm³
• Vapor Pressure: 5.12E-05mmHg at 25°C
• Refractive Index: 1.53
• CAS DataBase Reference: CYCLOPENTYL-(2,4-DIMETHOXY-BENZYL)-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPENTYL-(2,4-DIMETHOXY-BENZYL)-AMINE(356092-74-5)
• EPA Substance Registry System: CYCLOPENTYL-(2,4-DIMETHOXY-BENZYL)-AMINE(356092-74-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 356092-74-5(Hazardous Substances Data)

Usage

Uses

N-(2,4-Dimethoxybenzyl)cyclopentanamine is a reactant in the preparation of heteroarylsulfonamides as acetyl-lysine mimetics for BET bromodomain inhibition.

InChI:InChI=1/C14H21NO2/c1-16-13-8-7-11(14(9-13)17-2)10-15-12-5-3-4-6-12/h7-9,12,15H,3-6,10H2,1-2H3

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 1003-03-8 Cyclopentamine 

Relevant articles and documents

Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition

The ability of various functional groups to engage the acetyl-lysine (KAc) binding site within bromo- and extra-terminal domain (BET) protein family members BRD2, BRD3 and BRD4 was evaluated by screening small molecular fragments-coupled to a known arylsulfonamide scaffold-in biochemical inhibition assays. Useful structure activity relationships have been established and novel functional groups that bind to the KAc binding pocket identified. Additional microsomal degradation studies were also undertaken revealing significant differences in metabolic stability between two commonly employed BET inhibitor fragments.